查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
消毒帽市场：2023年至2028年预测
市场调查报告书
商品编码
1410099

消毒帽市场：2023年至2028年预测

Disinfection Cap Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计消毒盖市场在预测期内将以 8.03% 的复合年增长率成长。

消毒盖可作为防止微生物污染的额外防御层，以减少与医疗设备相关的疾病发生率。医疗相关感染疾病和癌症患者数量的增加是消毒盖市场的主要成长动力。此外，对感染控制的日益关注、意识的提高以及产品的推出预计将进一步加强消毒剂瓶盖市场。

医疗感染疾病(HAI) 盛行率不断上升

HAI 的流行是消毒盖市场的主要成长要素。据世界卫生组织称，每 100 名急诊医院患者中，高所得国家有 7 名患者和中低收入国家有 15 名患者在住院期间至少发生一种医疗保健相关感染 (HAI)。据世界卫生组织称，预计这些患者中平均有十分之一死于医院感染。此外，根据 CDC资料，从 2020 年到 2021 年，美国耐甲氧西林金黄色葡萄球菌 (MRSA) 的盛行率增加了 14%，2021 年人工呼吸器相关事件 (VAE) 增加了 12%。

癌症患者增加

消毒帽市场主要是由癌症发病率上升推动的，因为它们被用来清洗静脉注射连接。例如，根据世界卫生组织的数据，癌症是导致死亡的主要原因，2020 年全球将有超过 1,000 万人死于癌症。此外，据 WCRF 称，2020 年全球将诊断出约 1,800 万名新癌症患者。癌症患者的免疫力可能较弱，因此在癌症治疗期间实施适当的感染控制以尽量减少感染疾病风险非常重要。消毒帽是癌症患者的必需品，因为感染疾病使治疗和康復过程更加复杂。

医疗保健支出增加

医疗保健支出的成长推动了对先进医疗设备和感染控制产品的需求，从而推动了消毒盖市场。例如，根据世界卫生组织的报告，由于政府支出和外部援助的增加，2020年全球卫生支出将超过9兆美元。世卫组织报告显示，世卫组织50个成员国中有超过三分之二的卫生系统管治和管理支出平均增加了7%。随着医疗保健提供者投资于改善患者治疗效果并减少与感染疾病相关的总体成本负担的产品，消毒盖市场正受益于此趋势。

日益重视感染控制

感染控製程序越来越受到医疗机构和监管机构的关注。严格的法规和标准已经到位，以提高病人安全并减少医院感染的发生频率。政府机构正在组织各种计划来减少感染疾病和医院感染，这正在推动消毒盖市场的发展。例如，新兴感染疾病计画 (EIB) 是由 CDC 与美国农业部和其他 10 个美国机构合作进行的。 EIB 使用被称为 ABC 的主动实验室和基于人群的监测系统来监测对公共卫生具有重要意义的侵入性细菌感染。感染预防和控制（IPC）是世界卫生组织制定的一项实用的、基于证据的策略，旨在避免可能伤害患者和相关人员的感染疾病。

市场抑制因素

儘管消毒瓶盖市场正在不断成长和开拓，但也存在影响市场扩张的抑制因素和挑战。例如，医疗保健专业人员和患者对消毒剂瓶盖的好处和意义的了解有限可能会限制市场扩张。此外，由于市面上的医疗设备种类繁多，因此很难保持消毒盖的通用相容性。此外，遵守法律规章和获得必要认证所需的时间和成本可能会减缓消毒市场的成长并限制新的进入。

北美地区预计将大幅成长

预计在预测期内，北美地区将占据消毒盖市场的主要份额。推动该地区市场成长的因素包括医院感染数量的增加、强大的医疗保健系统、强有力的政府计划以及对感染负面影响的认识不断提高。例如，据脓毒症联盟称，美国每年有超过 60,000 名严重脓毒症患者接受紧急医疗服务治疗，这一数字被认为比心臟病和中风患者的总合还多。此外，由于该地区是 3M、B Braun 和 ICU Medical 等主要消毒盖製造商和经销商的所在地，预计该市场还将扩大。

主要市场参与者

3M是一家总部位于美国的跨国集团。 3M 提供广泛的产品、技术和解决方案，旨在改善患者治疗效果、感染预防和整体医疗保健效率。这种含酒精的盖子称为 3MTM Curos(TM) 无针连接器消毒盖，可旋入连接埠进行消毒和屏蔽。 ICU Medical 提供各种产品和解决方案，包括输液系统、静脉导管、重症加护监护和无针连接器。该公司开发的SwabCap(TM)消毒帽是无菌的，独立包装，可在30秒内消毒，有效期长达7天。 Omnia Health 为医疗保健专业人员和供应商提供各种服务和解决方案，包括创新解决方案和咨询。 iVCAP 由该公司设计，用作拭子鲁尔接入阀的盖子，以保护它们免受潜在污染。 Becton Dickinson 业务遍及医疗保健产业的各个领域，包括医疗机构、生命科学研究和临床测试。 BD PureHub(TM) 消毒盖不仅充当管线接入之间的物理屏障，而且还充当在接入之前清洗可擦拭、无针鲁尔连接的工具。

新兴市场的主要发展

2019年11月，Asset Medical发布了最新产品「SwabArt(R)消毒帽」。这是一种一次性消毒产品，使用浸有 70% IPA 的高吸水性海绵来防止感染。 2019 年 11 月，ICU Medical 宣布以 7,500 万美元收购 Pursuit Vascular, Inc.，以扩展其无针 IV 连接器和其他感染控制技术。 Pursuit Vascular 的主要产品是 ClearGuard(R) HD 帽，用于维护血液透析机导管。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章消毒盖市场：依类型

  • 介绍
  • 双帽系统
  • 单上限系统

第六章消毒帽市场：依经销商分类

  • 介绍
  • 零售
  • 非零售

第七章消毒帽市场：依最终用途分类

  • 介绍
  • 医院
  • 诊所
  • 其他的

第八章消毒帽市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • 3M Company
  • Acclima, Inc.
  • ICU Medical
  • Omnia Health
  • B. Braun
  • Becton Dickinson
  • Merit Pharmaceuticals
  • Innovamedia
  • Dr. Schumacher GmbH
  • Medline
简介目录
Product Code: KSI061615768

The disinfection cap market is estimated to grow at a CAGR of 8.03% during the forecast period.

Disinfectant caps serve as an extra layer of defense against microbial contamination to lower the incidence of illnesses linked to medical equipment. The growing prevalence of healthcare-acquired infections and cancer cases are major growth drivers in the disinfection cap market. Moreover, the increasing emphasis on infection control and rising awareness coupled with enhanced product launches are further expected to bolster the disinfection cap market.

Growing Prevalence of Healthcare-acquired Infections (HAIs)

The growing prevalence of HAIs is a major growth driver of the disinfection cap market. According to the WHO, seven patients in high-income countries and 15 patients in low- and middle-income countries out of every 100 patients in acute-care hospitals acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, one in ten of these patients is expected to die from their HAI as per the WHO. Moreover, the methicillin-resistant Staphylococcus aureus (MRSA) prevalence rate in the USA increased by 14% in 2021 from 2020 and ventilator-associated events (VAE) increased by 12% in 2021 as per the CDC data.

Increasing Cancer Cases

The disinfection cap market is being driven in large part by the rising incidence of cancer as these are used to clean IV connections. For instance, cancer is the leading death cause with more than 10 million worldwide deaths in 2020 according to the WHO. There were around 18 million new cancer cases worldwide in 2020 as per the WCRF. It is important to maintain proper infection control practices during cancer treatment to minimize the risk of infections, as cancer patients may have compromised immune systems. Infections can further complicate the treatment and recovery process therefore disinfection cap is a necessary component for cancer patients.

Rising Healthcare Expenditure

Increasing healthcare expenditure is driving the demand for advanced medical devices and infection control products thereby propelling the disinfection cap market. For instance, global health spending topped $9 trillion in 2020 owing to increased government spending and external aid as per the WHO report. In more than two-thirds of the 50 WHO nations, spending on health system governance and administration increased by an average of 7%. The disinfection cap market benefits from this trend as healthcare providers invest in products that improve patient outcomes and reduce the overall cost burden associated with infections.

Increased Emphasis on Infection Control

Infection control procedures are receiving more attention from healthcare facilities and regulatory agencies. To enhance patient safety and lower the frequency of HAIs, strict restrictions and standards are being introduced. Various programs are being organized by the government institution to reduce infections and HAIs which is aiding the disinfection cap market. For instance, the Emerging Infections Program (EIB) is being run by CDC in collaboration with the US Department of Agriculture, and 10 other US sites. An active laboratory- and population-based surveillance system called ABCs is used to monitor invasive bacterial infections that are significant for public health and is used by EIB. IPC (infection prevention and control) is a realistic, evidence-based strategy developed by the WHO for avoiding infections that might damage patients and healthcare professionals.

Restraints in the Market

The disinfection cap market has experienced growth and development, however, some restraints or challenges can impact its expansion. For example, healthcare professionals and patients' limited knowledge of the advantages and significance of disinfection caps may restrain market expansion. Moreover, due to the variety of medical equipment in the market, maintaining universal compatibility of disinfection caps might be difficult. Additionally, meeting regulatory compliance and obtaining necessary certifications can be time-consuming and expensive, potentially slowing down the disinfection market growth and limiting the entry of new players.

North America is Expected to Grow Significantly

The North American region is anticipated to hold a significant share of the disinfection cap market during the forecasted period. Various factors propelling the market growth in the region are higher HAIs, the presence of a strong healthcare system, robust government programs, and increased awareness about the adverse effects of infection. For instance, over 60,000 more severe sepsis patients are thought to be treated by emergency medical services in the United States each year than heart attack and stroke patients combined as per the Sepsis Alliance. Moreover, the presence of major producers and distributors of disinfection caps in the region such as 3M, B Braun, and ICU Medical is further expected to aid the market expansion.

Major Market Players

  • 3M is a multinational conglomerate corporation headquartered in the United States. 3M offers a wide array of products, technologies, and solutions aimed at improving patient outcomes, infection prevention, and overall healthcare efficiency. An alcohol-containing cap called the 3MTM Curos™ Disinfecting Cap for Needleless Connectors twists onto ports to disinfect and shield them.
  • ICU Medical offers a diverse portfolio of products and solutions including infusion systems, IV catheters, critical care monitoring, and needleless connectors. SwabCap™ disinfecting cap developed by the company offers individual sterile packaging and the ability to disinfect within 30 seconds for up to 7 days.
  • Omnia Health offers various services and solutions to healthcare providers and suppliers including innovative solutions and consultations. I.V. CAPs are designed by the company to be used as a cover over swab-able luer access valves to shield them from potential contamination.
  • Becton Dickinson operates across various segments of the healthcare industry, including healthcare institutions, life sciences research, and clinical laboratories. In addition to serving as a physical barrier between line accesses, the BD PureHub™ disinfection cap also serves as a tool for cleaning swabbable needle-free luer connections before access.

Key Market Developments

  • In November 2019, Asset Medical announced its newest product the SwabArt® Disinfection Cap. These are single-use disinfection product that protects from infection through a highly liquid absorbent sponge saturated with 70% of IPA.
  • In November 2019, ICU Medical announced the acquisition of Pursuit Vascular, Inc for $75 million to expand its needle-free IV connector and other infection control technologies. The primary product of Pursuit Vascular was the ClearGuard® HD cap which is used for the maintenance of hemodialysis catheters.

Segmentation:

By Type

  • Double Cap System
  • Single Cap System

By Distributor

  • Retail
  • Non-retail

By End-Use

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DISINFECTION CAP MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Double Cap System
  • 5.3. Single Cap System

6. DISINFECTION CAP MARKET, BY DISTRIBUTOR

  • 6.1. Introduction
  • 6.2. Retail
  • 6.3. Non-retail

7. DISINFECTION CAP MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Clinics
  • 7.4. Others

8. DISINFECTION CAP MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. 3M Company
  • 10.2. Acclima, Inc.
  • 10.3. ICU Medical
  • 10.4. Omnia Health
  • 10.5. B. Braun
  • 10.6. Becton Dickinson
  • 10.7. Merit Pharmaceuticals
  • 10.8. Innovamedia
  • 10.9. Dr. Schumacher GmbH
  • 10.10. Medline